Compare USLM & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | TARS |
|---|---|---|
| Founded | 1948 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | USLM | TARS |
|---|---|---|
| Price | $127.31 | $81.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $76.56 |
| AVG Volume (30 Days) | 64.5K | ★ 419.7K |
| Earning Date | 02-02-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ 32.23 | N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | $364,849,000.00 | ★ $366,100,000.00 |
| Revenue This Year | $22.64 | $147.24 |
| Revenue Next Year | $8.38 | $53.11 |
| P/E Ratio | $28.75 | ★ N/A |
| Revenue Growth | 20.27 | ★ 182.44 |
| 52 Week Low | $80.47 | $38.51 |
| 52 Week High | $151.16 | $85.25 |
| Indicator | USLM | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 61.85 |
| Support Level | $120.24 | $78.10 |
| Resistance Level | $131.47 | $83.34 |
| Average True Range (ATR) | 3.92 | 3.12 |
| MACD | 1.08 | -0.34 |
| Stochastic Oscillator | 43.42 | 52.75 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.